Adagene to Participate in Two Investor Conferences in September

Rhea-AI Summary

Adagene (Nasdaq: ADAG), a company focused on antibody-based therapy development, announced its participation in two upcoming investor conferences in New York this September.

The company's Chief Strategy Officer, Mickael Chane-Du, will attend the H.C. Wainwright Global Investment Conference on September 8 at 11:00 AM ET and the Morgan Stanley Global Healthcare Conference on September 10 at 7:00 AM ET. Both events will feature fireside chats and one-on-one investor meetings.

Webcasts of the presentations will be available on Adagene's website for 30 days following the events.

SAN DIEGO and SUZHOU, China, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene or the Company”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced that Adagene’s Chief Strategy Officer, Mickael Chane-Du, will participate in one-on-one investor meetings and a fireside chat at two investor conferences in September, both taking place in New York, New York.

H.C. Wainwright 27th Annual Global Investment Conference

• Fireside Chat Date: Monday, September 8
• Fireside Chat Time: 11:00 AM (Eastern Time)
• Location: Lotte New York Palace Hotel
• Webcast: https://journey.ct.events/view/5c4a1cf5-b8ef-4b48-ae46-3a0f5912b3ca

Morgan Stanley 23rd Annual Global Healthcare Conference

• Fireside Chat Date: Wednesday, September 10
• Fireside Chat Time: 7:00 AM (Eastern Time)
• Location: Sheraton New York Times Square Hotel
• Webcast: https://cc.webcasts.com/morg007/090825a_js/?entity=139_6SK4L3R

A webcast of the presentations will be accessible in the Investors section of the company’s website at https://www.adagene.com for at least 30 days.

About Adagene
Adagene Inc. (Nasdaq: ADAG) is a platform-driven, clinical-stage biotechnology company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. Adagene combines computational biology and artificial intelligence to design novel antibodies that address globally unmet patient needs. The company has forged strategic collaborations with reputable global partners that leverage its SAFEbody^® precision masking technology in multiple approaches at the vanguard of science.

Powered by its proprietary Dynamic Precision Library (DPL) platform, composed of NEObody™, SAFEbody, and POWERbody™ technologies, Adagene’s highly differentiated pipeline features novel immunotherapy programs. The company’s SAFEbody technology is designed to address safety and tolerability challenges associated with many antibody therapeutics by using precision masking technology to shield the binding domain of the biologic therapy. Through activation in the tumor microenvironment, this allows for tumor-specific targeting of antibodies in tumor microenvironment, while minimizing on-target off-tumor toxicity in healthy tissues.

Adagene’s lead clinical program, ADG126 (muzastotug), is a masked, anti-CTLA-4 SAFEbody that targets a unique epitope of CTLA-4 in regulatory T cells (Tregs) in the tumor microenvironment. ADG126 is currently in phase 1b/2 clinical studies in combination with anti-PD-1 therapy, particularly focused on Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC). Validated by ongoing clinical research, the SAFEbody platform can be applied to a wide variety of antibody-based therapeutic modalities, including Fc empowered antibodies, antibody-drug conjugates, and bi/multi-specific T-cell engagers.

For more information, please visit: https://investor.adagene.com.

Follow Adagene on WeChat, LinkedIn and X.

SAFEbody^® is a registered trademark in the United States, China, Australia, Japan, Singapore, and the European Union.

Investor Contacts:

Raymond Tam
raymond_tam@adagene.com

Corey Davis
LifeSci Advisors
cdavis@lifesciadvisors.com

FAQ

When is Adagene (ADAG) presenting at the H.C. Wainwright Conference in September 2025?

Adagene will present at the H.C. Wainwright Conference on Monday, September 8, 2025, at 11:00 AM ET at the Lotte New York Palace Hotel.

When is Adagene's presentation at the Morgan Stanley Healthcare Conference 2025?

Adagene will present at the Morgan Stanley Global Healthcare Conference on Wednesday, September 10, 2025, at 7:00 AM ET at the Sheraton New York Times Square Hotel.

Who will represent Adagene (ADAG) at the September 2025 investor conferences?

Mickael Chane-Du, Adagene's Chief Strategy Officer, will represent the company at both conferences.

How can investors access Adagene's conference presentations?

Investors can access the webcasts through the Investors section of Adagene's website at www.adagene.com, where they will be available for at least 30 days.